Merus announces appointment of Jason Avery as Chief Business Officer

June 18, 2012

Utrecht, The Netherlands, June 15, 2012 – Merus B.V., a biopharmaceutical company focused on multispecific human antibody therapeutics, announced today that Jason Avery has been appointed as Chief Business Officer.

With a professional background as Head of Business Development at Affitech A/S and Chief Business Officer at Cambridge Antibody Technology, Jason Avery brings extensive industry experience to Merus.

“Jason comes to Merus with a wealth of experience in Business Development, in particular in the antibody space, and we are delighted to have him join the team,” said Dr Ton Logtenberg, CEO of Merus B.V. “As our multispecific human antibody platforms have matured and consistently yield lead candidates for clinical development, Jason's expertise will be invaluable to reach our ambitious business goals.”

“Merus is one of the most impressive companies in the antibody technology and product space,” said Jason Avery. “The combination of MeMo®, the common light-chain transgenic mouse, and Merus’ antibody format technology facilitates unprecedented ease in the discovery, development and manufacturing of bispecific antibodies. I look forward to progressing the commercial success of Merus´ discriminative pipeline of owned and partnered antibody products. I am very excited to be joining such an experienced management team.”
###
About Merus B.V.
Merus is a biotechnology company that is applying its proprietary technologies to build a pipeline of innovative human therapeutic antibodies. These technologies support the generation of innovative antibody formats for improved clinical efficacy, e.g. bispecific antibodies or mixtures of antibodies. Merus aims to demonstrate superior efficacy of these human, recombinant, antibody-based therapeutics in relevant preclinical models and further develop selected product candidates through early clinical testing in multiple therapeutic areas.

For further information, please visit our website at www.merus.nl

Media Inquiries:
Company Inquiries:
akampion
Merus B.V.
Dr. Ludger Wess or Ines-Regina Buth
Shelley Margetson, CFO
Tel.: +49 (0)40 88 16 59 64/ +49 (0)30 2363 2768
Padualaan 8
info(at)akampion.com
3584CH Utrecht, the Netherlands
Tel.: +31 (0)30 253 8800
s.margetson@merus.nl

-------------
Contact // Kontakt akampion Newswire:
Dr. Ludger Wess
Managing Partner, akampion
Hamburg Office
T: +49 (0)40 88 16 59 64
F: +49 (0)40 88 16 59 65
ludger@akampion.com
Ines-Regina Buth
Managing Partner, akampion
Berlin Office
T: +49 (0)30 23632768
F: +49 (0)30 23632769
ines@akampion.com

Home > Press Releases > Merus announces appointment of Jason Avery as C...

© 2019 Aglaia Oncology Funds | Privacy | Sitemap
Aglaia Oncology Funds